BACKGROUND: Patients with recurrent or progressive low grade gliomas survive for a decade or more following diagnosis, and may be at a higher risk for treatment-related complications, such as cognitive impairment from radiotherapy. PURPOSE: The aim of the present study was to determine in patients with progressive or recurrent low grade gliomas, the response rate and toxicity incurred by a continued schedule of temozolomide chemotherapy administered before radiation therapy, and to explore correlations between response and survival with 1p/19q deletions and MGMT promoter methylation status. METHODS: Progressive radio and chemotherapy naïve low grade glioma patients with O(6)-methyl-guanine-DNA-methyl-tranferase (MGMT) promoter status evaluation were considered eligible. Chemotherapy cycles consisted of temozolomide 75 mg/m(2)/daily for 21 days every 28 days for 12 cycles. RESULTS: A total of 30 patients (median age 45 [range: 24.2-68.6] years) with a median KPS of 90 (range 60-90) were accrued. The overall response rate was 30% (9 partial responses); 17 patients (56.7%) had disease stabilization. CONCLUSION: The prolonged temozolomide schedule considered in the present study is followed by a high response rate; toxicity is acceptable. Further randomized trials should therefore be conducted to confirm the efficacy of this regimen as first-line therapy in patients with progressive low grade glioma.
BACKGROUND:Patients with recurrent or progressive low grade gliomas survive for a decade or more following diagnosis, and may be at a higher risk for treatment-related complications, such as cognitive impairment from radiotherapy. PURPOSE: The aim of the present study was to determine in patients with progressive or recurrent low grade gliomas, the response rate and toxicity incurred by a continued schedule of temozolomide chemotherapy administered before radiation therapy, and to explore correlations between response and survival with 1p/19q deletions and MGMT promoter methylation status. METHODS: Progressive radio and chemotherapy naïve low grade gliomapatients with O(6)-methyl-guanine-DNA-methyl-tranferase (MGMT) promoter status evaluation were considered eligible. Chemotherapy cycles consisted of temozolomide 75 mg/m(2)/daily for 21 days every 28 days for 12 cycles. RESULTS: A total of 30 patients (median age 45 [range: 24.2-68.6] years) with a median KPS of 90 (range 60-90) were accrued. The overall response rate was 30% (9 partial responses); 17 patients (56.7%) had disease stabilization. CONCLUSION: The prolonged temozolomide schedule considered in the present study is followed by a high response rate; toxicity is acceptable. Further randomized trials should therefore be conducted to confirm the efficacy of this regimen as first-line therapy in patients with progressive low grade glioma.
Authors: A Tosoni; G Cavallo; M Ermani; L Scopece; E Franceschi; C Ghimenton; M Gardiman; L Pasetto; V Blatt; A A Brandes Journal: Neurology Date: 2006-02-14 Impact factor: 9.910
Authors: K Hoang-Xuan; J He; S Huguet; K Mokhtari; Y Marie; M Kujas; P Leuraud; L Capelle; J Y Delattre; J Poirier; P Broët; M Sanson Journal: Neurology Date: 2001-10-09 Impact factor: 9.910
Authors: A Pace; A Vidiri; E Galiè; M Carosi; S Telera; A M Cianciulli; P Canalini; D Giannarelli; B Jandolo; C M Carapella Journal: Ann Oncol Date: 2003-12 Impact factor: 32.976
Authors: K Hoang-Xuan; L Capelle; M Kujas; S Taillibert; H Duffau; J Lejeune; M Polivka; E Crinière; Y Marie; K Mokhtari; A F Carpentier; F Laigle; J M Simon; P Cornu; P Broët; M Sanson; J Y Delattre Journal: J Clin Oncol Date: 2004-08-01 Impact factor: 44.544
Authors: Manon van Engeland; Matty P Weijenberg; Guido M J M Roemen; Mirian Brink; Adriaan P de Bruïne; R Alexandra Goldbohm; Piet A van den Brandt; Stephen B Baylin; Anton F P M de Goeij; James G Herman Journal: Cancer Res Date: 2003-06-15 Impact factor: 12.701
Authors: A W Tolcher; S L Gerson; L Denis; C Geyer; L A Hammond; A Patnaik; A D Goetz; G Schwartz; T Edwards; L Reyderman; P Statkevich; D L Cutler; E K Rowinsky Journal: Br J Cancer Date: 2003-04-07 Impact factor: 7.640
Authors: A A Brandes; A Tosoni; G Cavallo; R Bertorelle; V Gioia; E Franceschi; M Biscuola; V Blatt; L Crinò; M Ermani Journal: Br J Cancer Date: 2006-10-03 Impact factor: 7.640
Authors: Grit Welzel; Julian Gehweiler; Stefanie Brehmer; Jens-Uwe Appelt; Andreas von Deimling; Marcel Seiz-Rosenhagen; Peter Schmiedek; Frederik Wenz; Frank A Giordano Journal: J Neurooncol Date: 2015-06-05 Impact factor: 4.130
Authors: David A Reardon; Annick Desjardins; James J Vredenburgh; James E Herndon; April Coan; Sridharan Gururangan; Katherine B Peters; Roger McLendon; Sith Sathornsumetee; Jeremy N Rich; Eric S Lipp; Dorothea Janney; Henry S Friedman Journal: Cancer Date: 2012-02-27 Impact factor: 6.860
Authors: Jasmin Jo; Brian Williams; Mark Smolkin; Max Wintermark; Mark E Shaffrey; M Beatriz Lopes; David Schiff Journal: J Neurooncol Date: 2014-07-20 Impact factor: 4.130
Authors: Mark R Gilbert; James Dignam; Stephanie Pugh; Terri S Armstrong; Jeffrey S Wefel; Ken Aldape; Roger Stupp; Monika Hegi; Minhee Won; Walter J Curran; Minesh P Mehta Journal: J Clin Oncol Date: 2014-04-21 Impact factor: 44.544
Authors: Johan A F Koekkoek; Melissa Kerkhof; Linda Dirven; Jan J Heimans; Jaap C Reijneveld; Martin J B Taphoorn Journal: Neuro Oncol Date: 2015-03-25 Impact factor: 12.300